CL2020002075A1 - Methods for treating cancer with anti-pd1 antibodies. - Google Patents

Methods for treating cancer with anti-pd1 antibodies.

Info

Publication number
CL2020002075A1
CL2020002075A1 CL2020002075A CL2020002075A CL2020002075A1 CL 2020002075 A1 CL2020002075 A1 CL 2020002075A1 CL 2020002075 A CL2020002075 A CL 2020002075A CL 2020002075 A CL2020002075 A CL 2020002075A CL 2020002075 A1 CL2020002075 A1 CL 2020002075A1
Authority
CL
Chile
Prior art keywords
antigen
methods
binding fragment
treating cancer
antibodies
Prior art date
Application number
CL2020002075A
Other languages
Spanish (es)
Inventor
Mallika Lala
Lokesh Jain
Mengyao Li
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67620026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020002075(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2020002075A1 publication Critical patent/CL2020002075A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con métodos para tratar cáncer en un paciente que comprende administrar un antagonista de PD-1, por ejemplo, un anticuerpo de anti-PD-1 o un fragmento de unión a antígeno del mismo (por ejemplo, pembrolizumab), en cantidades específicas al paciente aproximadamente cada seis semanas. En algunas modalidades, la cantidad del anticuerpo de anti-PD-1 o un fragmento de unión a antígeno del mismo es aproximadamente 400 mg. En ciertas modalidades, el antagonista de PD-1 es pembrolizumab o un fragmento de unión a antígeno del mismo. También se proporcionan las composiciones y kits que comprenden una dosis de un anticuerpo de anti-PD-1 o un fragmento de unión a antígeno del mismo y los usos del mismo para tratar cáncerThe present invention relates to methods for treating cancer in a patient comprising administering a PD-1 antagonist, eg, an anti-PD-1 antibody or an antigen-binding fragment thereof (eg, pembrolizumab), in patient-specific amounts approximately every six weeks. In some embodiments, the amount of the anti-PD-1 antibody or an antigen-binding fragment thereof is about 400 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab or an antigen-binding fragment thereof. Also provided are compositions and kits comprising a dose of an anti-PD-1 antibody or antigen-binding fragment thereof and uses thereof to treat cancer.

CL2020002075A 2018-02-13 2020-08-10 Methods for treating cancer with anti-pd1 antibodies. CL2020002075A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862630038P 2018-02-13 2018-02-13
US201862732828P 2018-09-18 2018-09-18

Publications (1)

Publication Number Publication Date
CL2020002075A1 true CL2020002075A1 (en) 2020-10-23

Family

ID=67620026

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002075A CL2020002075A1 (en) 2018-02-13 2020-08-10 Methods for treating cancer with anti-pd1 antibodies.

Country Status (14)

Country Link
US (2) US12358984B2 (en)
EP (1) EP3752180B1 (en)
JP (2) JP2021513541A (en)
KR (1) KR20200119844A (en)
CN (2) CN120919306A (en)
AU (2) AU2019220495B2 (en)
BR (1) BR112020016331A8 (en)
CA (2) CA3307689A1 (en)
CL (1) CL2020002075A1 (en)
IL (1) IL276303A (en)
MA (1) MA52789A (en)
MX (2) MX2020008445A (en)
SG (1) SG11202007590TA (en)
WO (1) WO2019160751A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2170959E (en) 2007-06-18 2014-01-07 Merck Sharp & Dohme ANTIBODIES FOR THE PD-1 PROGRAMMED DEATH HUMAN RECEPTOR
CN112203642B (en) 2019-03-25 2025-03-07 阿特根公司 Pharmaceutical composition comprising human hyaluronidase PH20 variant and a drug for subcutaneous injection
US20220380469A1 (en) 2019-09-27 2022-12-01 Merck Sharp & Dohme Corp. Methods for treating metastatic triple negative breast cancer with anti-pd-1 antibodies
JP2023510132A (en) * 2019-12-20 2023-03-13 メルク・シャープ・アンド・ドーム・エルエルシー Methods of treating cancer using combinations of PD-1 antagonists, ILT4 antagonists and chemotherapeutic agents
US20230355757A1 (en) 2019-12-20 2023-11-09 Formycon Ag Formulations of anti-pd1 antibodies
CN112326961B (en) * 2020-10-30 2021-08-06 福州迈新生物技术开发有限公司 Analysis method and storage device for proportion of PD-L1 positive tumor cells in non-small cell lung cancer
CN112394102B (en) * 2020-11-05 2023-05-26 上海交通大学医学院附属瑞金医院 Marker for detecting hypopituitarism and application thereof
US20240287185A1 (en) 2021-06-23 2024-08-29 Formycon Ag Formulations of anti-pd1 antibodies
WO2023003790A1 (en) * 2021-07-20 2023-01-26 Merck Sharp & Dohme Llc Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
CN113893343A (en) * 2021-10-16 2022-01-07 广州誉衡生物科技有限公司 anti-PD-1 antibody and application thereof in preparation of medicine for treating cervical cancer patient
WO2023114346A2 (en) * 2021-12-16 2023-06-22 Merck Sharp & Dohme Llc Biomarkers for predicting eligibility for an anti-ilt4 and anti-pd-1 combination therapy
US20260207493A1 (en) 2022-12-21 2026-07-23 Formycon Ag Formulations of anti-pd1 antibodies
CN115925954A (en) * 2022-12-28 2023-04-07 广州誉衡生物科技有限公司 anti-PD-1 antibody and application thereof in preparation of medicines for treating urothelial cancer patients
WO2025140467A1 (en) * 2023-12-29 2025-07-03 上海复宏汉霖生物技术股份有限公司 Stable high-concentration anti-pd-1 antibody pharmaceutical formulation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
ES2367430T3 (en) 2002-12-23 2011-11-03 Wyeth Llc ANTIBODIES AGAINST PD-1 AND ITS USES.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (en) * 2007-06-18 2014-01-07 Merck Sharp & Dohme ANTIBODIES FOR THE PD-1 PROGRAMMED DEATH HUMAN RECEPTOR
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
AR093984A1 (en) 2012-12-21 2015-07-01 Merck Sharp & Dohme ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
WO2014165422A1 (en) 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
MX2016007965A (en) 2013-12-17 2016-10-28 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists.
WO2016011357A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
US10695426B2 (en) * 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
KR20170080697A (en) 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 Checkpoint blockade and microsatellite instability
AR103726A1 (en) * 2015-02-27 2017-05-31 Merck Sharp & Dohme HUMAN ANTI-PD-1 MONOCLONAL ANTIBODY CRYSTALS
EP3288980B1 (en) * 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
CN108495651A (en) 2015-12-17 2018-09-04 诺华股份有限公司 The antibody molecule and application thereof of anti-PD-1
EP3405203A4 (en) 2016-01-22 2019-07-24 X4 Pharmaceuticals, Inc. METHODS OF TREATING CANCER
EP3408296A1 (en) 2016-01-27 2018-12-05 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
WO2017151502A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2017165125A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
TWI822521B (en) 2016-05-13 2023-11-11 美商再生元醫藥公司 Methods of treating skin cancer by administering a pd-1 inhibitor
US20190160148A1 (en) * 2016-05-23 2019-05-30 Eli Lilly And Company Combination of pembrolizumab and abemaciclib for the treatment of cancer
KR20250107295A (en) 2016-06-03 2025-07-11 브리스톨-마이어스 스큅 컴퍼니 Anti-pd-1 antibody for use in a method of treating a tumor
MX2019002946A (en) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anti-pd-1(cd279) antibodies.
PT3565844T (en) 2017-01-09 2023-05-02 Tesaro Inc Methods of treating cancer with anti-pd-1 antibodies
EP3630840A1 (en) * 2017-06-01 2020-04-08 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-pd-1 antibody

Also Published As

Publication number Publication date
EP3752180A4 (en) 2021-12-15
CA3090995A1 (en) 2019-08-22
US20210047408A1 (en) 2021-02-18
BR112020016331A2 (en) 2020-12-15
CA3307689A1 (en) 2026-05-13
KR20200119844A (en) 2020-10-20
MX2020008445A (en) 2020-09-28
JP2021513541A (en) 2021-05-27
JP2024038251A (en) 2024-03-19
AU2019220495B2 (en) 2025-11-13
EP3752180B1 (en) 2026-07-22
EP3752180A2 (en) 2020-12-23
US20240026003A1 (en) 2024-01-25
CN120919306A (en) 2025-11-11
WO2019160751A3 (en) 2020-09-10
CN111712255A (en) 2020-09-25
RU2020129827A (en) 2022-03-14
WO2019160751A2 (en) 2019-08-22
US12358984B2 (en) 2025-07-15
SG11202007590TA (en) 2020-09-29
MA52789A (en) 2021-04-14
AU2026201041A1 (en) 2026-03-05
IL276303A (en) 2020-09-30
AU2019220495A1 (en) 2020-08-13
BR112020016331A8 (en) 2023-02-07
MX2024013016A (en) 2024-11-08

Similar Documents

Publication Publication Date Title
MX2020008445A (en) Methods for treating cancer with anti-pd-1 antibodies.
MX2024007358A (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof.
MX2022001841A (en) ANTIBODIES AGAINST ILT2 AND USE THEREOF.
BR112020015915A8 (en) USES OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA4 ANTIBODY OR ANTIGEN-BINDING FRAGMENTS THEREOF, AS WELL AS A KIT FOR TREATMENT OF A PATIENT WITH CANCER
MX2017006312A (en) Methods for tumor treatment using cd3xcd20 bispecific antibody.
MX2019009772A (en) Anti-pd-1 antibodies for treatment of lung cancer.
CR20190162A (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
MX2020010913A (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs.
MX2017013270A (en) Compositions comprising a combination of an anti-pd-1 antibody and another antibody.
MX2021009041A (en) Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof.
CO2023002375A2 (en) Antibodies against ilt2 and use thereof
CL2017001756A1 (en) Dosing regimen for madcam antagonists.
ECSP23076276A (en) METHODS FOR THE TREATMENT OF CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES
CL2025001101A1 (en) Compositions and methods for the treatment of cancer with subcutaneous administration of anti-PD1 antibodies.
CL2023000121A1 (en) Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
MX2022001065A (en) ANTI-BCMA ANTIBODY, FRAGMENT BINDING TO THE ANTIGEN AND MEDICAL USE OF THE SAME.
MX2021013248A (en) DOSAGE REGIMENS FOR ANTI-RSV ANTIBODIES AND COMPOSITIONS INCLUDING THEM.
MX2022003610A (en) DOSE ADMINISTRATION FOR TREATMENT WITH ANTI-TIGIT AND ANTI-PD-L1 ANTAGONIST ANTIBODIES.
MX2023015070A (en) Anti-cd40 antibody, antigen-binding fragment and medical use thereof.
AR110620A1 (en) COMBINED THERAPIES OF CHEMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS
DOP2025000008A (en) PHARMACEUTICAL COMPOSITION OF ANTI-CD20 ANTIBODY AND ITS USE
MX2022005245A (en) DOSAGE REGIME OF ANTI-CD27 ANTIBODIES FOR THE TREATMENT OF CANCER.
PE20250161A1 (en) Doses for treatment with bispecific antibodies anti-CD20/anti-CD3 in elderly patients
AR130745A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES
MX2022006883A (en) Use of isatuximab for the treatment of relapsed and/or refractory multiple myeloma.